Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker NVS · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Oct 28, 2026 | PIQRAY ALPELISIB | NVS Novartis | New drug (NDA), supplement Labeling | NDA212526 ↗ |
| Oct 15, 2026 | COSENTYX SECUKINUMAB | NVS Novartis Pharmaceuticals Corp | Biologic (BLA), supplement Efficacy | BLA761349 ↗ |
| Oct 15, 2026 | COSENTYX SECUKINUMAB | NVS Novartis Pharmaceuticals Corp | Biologic (BLA), supplement Labeling | BLA125504 ↗ |
| Oct 6, 2026 | RHAPSIDO REMIBRUTINIB | NVS Novartis | New drug (NDA), supplement Efficacy | NDA218436 ↗ |
| Sep 22, 2026 | SCEMBLIX ASCIMINIB HYDROCHLORIDE | NVS Novartis | New drug (NDA), supplement Labeling | NDA215358 ↗ |
| Sep 16, 2026 | ZORTRESS EVEROLIMUS | NVS Novartis | New drug (NDA), supplement Labeling | NDA021560 ↗ |
| Aug 19, 2026 | LEQVIO INCLISIRAN SODIUM | NVS Novartis | New drug (NDA), supplement Labeling | NDA214012 ↗ |
| Jul 31, 2026 | PLUVICTO LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN | NVS Novartis | New drug (NDA), supplement Efficacy | NDA215833 ↗ |
| Jul 29, 2026 | MYFORTIC MYCOPHENOLATE SODIUM | NVS Novartis | New drug (NDA), supplement REMS | NDA050791 ↗ |
| Jul 29, 2026 | MYFORTIC MYCOPHENOLATE SODIUM | NVS Novartis | New drug (NDA), supplement Labeling | NDA050791 ↗ |
| Jul 16, 2026 | FABHALTA IPTACOPAN HYDROCHLORIDE | NVS Novartis | New drug (NDA), supplement Efficacy | NDA218276 ↗ |
| Jul 15, 2026 | TEGRETOL XR CARBAMAZEPINE | NVS Novartis | New drug (NDA), supplement Labeling | NDA020234 ↗ Letter or label ↗ |
| Jul 15, 2026 | TEGRETOL CARBAMAZEPINE | NVS Novartis | New drug (NDA), supplement Labeling | NDA018927 ↗ Letter or label ↗ |
| Jul 15, 2026 | TEGRETOL CARBAMAZEPINE | NVS Novartis | New drug (NDA), supplement Labeling | NDA016608 ↗ Letter or label ↗ |
| Jul 13, 2026 | GLEEVEC IMATINIB MESYLATE | NVS Novartis | New drug (NDA), supplement Labeling | NDA021588 ↗ |
| Jul 1, 2026 | KISQALI FEMARA CO-PACK (COPACKAGED) LETROZOLE; RIBOCICLIB SUCCINATE | NVS Novartis | New drug (NDA), supplement Efficacy | NDA209935 ↗ |
| Jul 1, 2026 | KISQALI RIBOCICLIB SUCCINATE | NVS Novartis | New drug (NDA), supplement Efficacy | NDA209092 ↗ |
| Jun 30, 2026 | MAYZENT SIPONIMOD | NVS Novartis | New drug (NDA), supplement Labeling | NDA209884 ↗ |
| Jun 1, 2026 | AFINITOR DISPERZ EVEROLIMUS | NVS Novartis Pharm | New drug (NDA), supplement Labeling | NDA203985 ↗ Letter or label ↗ |
| Jun 1, 2026 | AFINITOR EVEROLIMUS | NVS Novartis | New drug (NDA), supplement Labeling | NDA022334 ↗ Letter or label ↗ |
| May 29, 2026 | SANDIMMUNE CYCLOSPORINE | NVS Novartis | New drug (NDA), supplement Labeling | NDA050574 ↗ Letter or label ↗ |
| May 7, 2026 | MEKINIST TRAMETINIB DIMETHYL SULFOXIDE | NVS Novartis | New drug (NDA), supplement Labeling | NDA204114 ↗ |
| Apr 17, 2026 | COSENTYX SECUKINUMAB | NVS Novartis Pharmaceuticals Corp | Biologic (BLA), supplement Labeling | BLA761349 ↗ |
| Apr 17, 2026 | COSENTYX SECUKINUMAB | NVS Novartis Pharmaceuticals Corp | Biologic (BLA), supplement Labeling | BLA761349 ↗ |
| Apr 17, 2026 | COSENTYX SECUKINUMAB | NVS Novartis Pharmaceuticals Corp | Biologic (BLA), supplement Efficacy | BLA125504 ↗ |
| Apr 17, 2026 | COSENTYX SECUKINUMAB | NVS Novartis Pharmaceuticals Corp | Biologic (BLA), supplement Efficacy | BLA125504 ↗ |
| Apr 14, 2026 | SCEMBLIX ASCIMINIB HYDROCHLORIDE | NVS Novartis | New drug (NDA), supplement Manufacturing (CMC) | NDA215358 ↗ |
| Apr 7, 2026 | PLUVICTO LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN | NVS Novartis | New drug (NDA), supplement Labeling | NDA215833 ↗ |
| Apr 1, 2026 | KESIMPTA OFATUMUMAB | NVS Novartis | Biologic (BLA), supplement Labeling | BLA125326 ↗ |
| Mar 26, 2026 | TAFINLAR DABRAFENIB MESYLATE | NVS Novartis | New drug (NDA), supplement Labeling | NDA217514 ↗ Letter or label ↗ |
| Mar 26, 2026 | MEKINIST TRAMETINIB; TRAMETINIB DIMETHYL SULFOXIDE | NVS Novartis | New drug (NDA), supplement Labeling | NDA217513 ↗ Letter or label ↗ |
| Mar 26, 2026 | MEKINIST TRAMETINIB DIMETHYL SULFOXIDE | NVS Novartis | New drug (NDA), supplement Labeling | NDA204114 ↗ Letter or label ↗ |
| Mar 26, 2026 | TAFINLAR DABRAFENIB MESYLATE | NVS Novartis | New drug (NDA), supplement Labeling | NDA202806 ↗ Letter or label ↗ |
| Mar 12, 2026 | COSENTYX SECUKINUMAB | NVS Novartis Pharmaceuticals Corp | Biologic (BLA), supplement Labeling | BLA761349 ↗ |
| Mar 12, 2026 | COSENTYX SECUKINUMAB | NVS Novartis Pharmaceuticals Corp | Biologic (BLA), supplement Efficacy | BLA125504 ↗ |
| Mar 6, 2026 | SANDIMMUNE CYCLOSPORINE | NVS Novartis | New drug (NDA), supplement Labeling | NDA050625 ↗ |
| Mar 6, 2026 | SANDIMMUNE CYCLOSPORINE | NVS Novartis | New drug (NDA), supplement Labeling | NDA050574 ↗ |
| Mar 6, 2026 | SANDIMMUNE CYCLOSPORINE | NVS Novartis | New drug (NDA), supplement Labeling | NDA050573 ↗ |
| Feb 12, 2026 | LEQVIO INCLISIRAN SODIUM | NVS Novartis | New drug (NDA), supplement Efficacy | NDA214012 ↗ |
| Feb 12, 2026 | LEQVIO INCLISIRAN SODIUM | NVS Novartis | New drug (NDA), supplement Efficacy | NDA214012 ↗ |
| Jan 14, 2026 | GLEEVEC IMATINIB MESYLATE | NVS Novartis | New drug (NDA), supplement Labeling | NDA021588 ↗ |
| Nov 25, 2025 | SCEMBLIX ASCIMINIB HYDROCHLORIDE | NVS Novartis | New drug (NDA), supplement Efficacy | NDA215358 ↗ |
| Oct 20, 2025 | VANRAFIA ATRASENTAN HYDROCHLORIDE | NVS Novartis | New drug (NDA), supplement Labeling | NDA219208 ↗ |
| Oct 2, 2025 | SCEMBLIX ASCIMINIB HYDROCHLORIDE | NVS Novartis | New drug (NDA), supplement Efficacy | NDA215358 ↗ |
| Sep 30, 2025 | RHAPSIDO REMIBRUTINIB | NVS Novartis | New drug (NDA) Type 1 - New Molecular Entity | NDA218436 ↗ Letter or label ↗ |
| Sep 30, 2025 | TEGRETOL XR CARBAMAZEPINE | NVS Novartis | New drug (NDA), supplement Labeling | NDA020234 ↗ Letter or label ↗ |
| Sep 30, 2025 | TEGRETOL CARBAMAZEPINE | NVS Novartis | New drug (NDA), supplement Labeling | NDA018927 ↗ |
| Sep 30, 2025 | TEGRETOL CARBAMAZEPINE | NVS Novartis | New drug (NDA), supplement Labeling | NDA016608 ↗ |
| Sep 23, 2025 | TRILEPTAL OXCARBAZEPINE | NVS Novartis | New drug (NDA), supplement Labeling | NDA021285 ↗ |
| Sep 23, 2025 | TRILEPTAL OXCARBAZEPINE | NVS Novartis | New drug (NDA), supplement Labeling | NDA021014 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 6:50 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates